GTA(input): for Friday 06/23/2006

[eliteG]

G-TA

Stock opinions and chart analysis after-market close. 

Input your stock(s) and some reasons..

Check G-TA(output) for the review. 

[usedcasting]

Hey G, hope things are well. Could I get your opinion on CRAYD. With the recent reverse split and some upward momo over the last six days I was interested in your take.

Thanks

uc.

[nullzero]

G was wondering what you thought of short position on NEW. Giving the bearish outlook on the real estate and real estate lending I took up a position short in NEW. Averaged in at about 45.55.

[Amarens]

Hi G,

Having trouble uploading charts. I'm interested to hear whot you think about ANX. Positive news is expected this summer, but the chart still shows no direction really. I've been in and out for the last months getting small profits.

What do you think?

And sorry about the charts, working on a different computer.

Amarens

[la-onda]

Hi G.,
what about NOVC?
ovacea rises on positive coverage start
Monday , June 19, 2006 12:36 ET

By Staff Reporter

NEW YORK, Jun 19, 2006 (XFN-ASIA via COMTEX) -- Shares of Novacea Inc. rose Monday after a group of analysts initiated positive coverage on the biotech drug developer based on its experimental cancer treatments.

Novacea shares rose 41 cents, or 6.6 percent, to $6.61 in late morning trading on the Nasdaq. The stock began trading on May 11 priced at $6.50, and have traded between $6.01 and $7.37.

Investment firms Bear Stearns, Pacific Growth Equities, Cowen & Co., and HSBC all initiated coverage of the South San Francisco, Calif.-based company with Buy-grade ratings.

Analysts all pointed to mid-stage clinical data showing DN-101, when used along with Sanofi-Aventis SA's Taxotere, significantly lowering the risk of death and adverse events in advanced-stage prostate cancer patients.

In a note, Bear Stearns analyst Akhtar Samad fixed a target price of $10 and said that Novacea set itself apart from other small biotechs by conducting a large, controlled mid-stage clinical trial on the drug with Taxotere versus Taxotere alone. The analyst called the 49 percent improvement in survival time with both drugs "impressive," and forecast U.S. sales to peak at about $180 million in 2012.

Pacific Growth Equities analyst Gregory Wade took an even more optimistic view of the drug and set his sales forecast nearly four times higher. Wade estimates DN-101 sales of $647 million by 2011, with those approaching $1 billion by 2015.

Cowen & Co. analyst Eric Schmidt, who rates the company an "Outperform," said the treatment could transform the prostate cancer market.

HSBC analyst Gene Mack set a $12 price target, and estimated DN-101 would generate $149 million in first year sales after a 2010 launch with sales peaking between $540 million and $720 million.

Novacea is also developing a treatment for breast and lung cancer called vinorelbine, and a brain cancer treatment called AQ4N.

[la-onda]

hoops, I have forgotten to ask for your ENCY feedback ?
ENCY:
Encysive Pharmaceuticals (formerly Texas Biotechnology Corporation), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs, is recognized for our expertise in small molecule drug development and vascular biology. Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III development of the endothelin antagonist, sitaxsentan, for pulmonary arterial hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in Phase II development with the selectin antagonist bimosiamose in asthma, psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other research and development programs ongoing for a range of cardiovascular and inflammatory diseases.
&
ENCY: Leerink Swann Ups to Mkt Perform from Underperform; Sets Tgt @ $9; Analyst Notes
Friday , June 16, 2006 11:00 ET
Issuer: Encysive Pharmaceuticals, Inc. (NasdaqNM: ENCY)
Analyst Firm:  Leerink Swann & Company
Ratings Action: UPGRADE
Current Rating: Mkt Perform (from Underperform)
Target Price Action: INITIATE
Target Price: $9.00
Analyst Comments: According to the firm, the FDA accepted ENCY's complete response to Thelin's March 24 approvable letter and that based on the positive momentum they are upgrading their rating to Market Perform from Underperform. They see a US launch of Thelin to come sometime in Q3 2006. They raised revenue estimates for '06 to $24M from 15M, '07 to $99M from $34M, '08 to $184M from $58M, and '09 to $297M from $153M. They also raised EPS estimates for '06 to ($1.84) from ($1.92), '07 to (68c) from (80c), '08 to 35c from (41c), and '09 to $1.73 from 36c.